Arcadia Biosciences Inc
$ 1.32
0.38%
13 Apr - close price
- Market Cap 2,715,100 USD
- Current Price $ 1.32
- High / Low $ 1.39 / 1.31
- Stock P/E N/A
- Book Value 3.02
- EPS -1.71
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.33 %
- ROE -0.45 %
- 52 Week High 5.72
- 52 Week Low 1.30
About
Arcadia Biosciences, Inc. is dedicated to developing various crop productivity traits primarily in hemp, wheat, and soybeans. The company is headquartered in Davis, California.
Analyst Target Price
$12.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-27 | 2025-11-07 | 2025-08-14 | 2025-05-07 | 2025-03-26 | 2024-11-12 | 2024-08-13 | 2024-05-22 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.9759 | 0.62 | -3.26 | 1.9 | -2.99 | -0.87 | 0.78 | -1.78 | -2.52 | -1.44 | -2.65 | -10.86 |
| Estimated EPS | None | -0.94 | -1.22 | -0.98 | -0.89 | -0.81 | 1.55 | -2.21 | -2.58 | -3.19 | -4.8 | -6.85 |
| Surprise | 0 | 1.56 | -2.04 | 2.88 | -2.1 | -0.06 | -0.77 | 0.43 | 0.06 | 1.75 | 2.15 | -4.01 |
| Surprise Percentage | None% | 165.9574% | -167.2131% | 293.8776% | -235.9551% | -7.4074% | -49.6774% | 19.457% | 2.3256% | 54.8589% | 44.7917% | -58.5401% |
Next Quarterly Earnings
| Apr 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RKDA
2026-04-04 17:11:17
This article analyzes Arcadia Biosciences Inc (RKDA) valuation, stating it is currently in the "Fair zone" with a forward PS ratio of 0.36 compared to its five-year average of 0.71. The fair price for RKDA is estimated to be between $1.08 and $7.79 using a relative valuation method. Despite appearing fair, its P/S ratio is above the industry average, and a negative revenue growth rate suggests this premium might be unsustainable.
2026-04-03 20:09:28
Arcadia Biosciences announced the dismissal of Deloitte & Touche LLP as its independent auditor, effective March 30, and has appointed Ramirez Jimenez International CPAs (RJI) for future financial statement reviews and audits. Deloitte's previous audit reports included an explanatory paragraph about Arcadia's ability to continue as a going concern due to recurring losses and insufficient resources. The company identified material weaknesses in internal control over financial reporting for 2025, primarily due to reduced employee headcount impacting segregation of duties and information system controls.
2026-04-03 19:09:28
Arcadia Biosciences (RKDA) has switched its independent auditor from Deloitte & Touche to Ramirez Jimenez International CPAs (RJI) due to ongoing financial and control issues. Deloitte's previous reports included a going-concern explanatory paragraph, and the company continues to disclose material weaknesses in internal control over financial reporting, exacerbated by reduced employee headcount. Despite the auditor change, the company states there were no disagreements on accounting principles.
2026-04-02 07:40:43
This page provides a comprehensive overview of Arcadia Biosciences (RKDA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event filings. It details recent significant events such as updates on the proposed all-stock combination with Roosevelt Resources, LP, changes in executive roles, and financial disclosures. The platform offers AI-powered summaries and sentiment analysis for these regulatory documents to assist investors.
2026-04-01 10:39:17
This article provides recent news and events related to RKDA (Arcadia Biosciences) stock. Key updates include Arcadia Biosciences' Q4 financial results, termination of an agreement with Roosevelt Resources, and recent filings and investment options. It also highlights Rockwell Medical's Q4 financial performance and extension of an agreement with a major US dialysis provider.
2026-03-27 13:40:08
Arcadia Biosciences (RKDA) reported a net income of USD -1.336 million for the fourth quarter. This brief financial update was provided by Refinitiv and is relevant to investors tracking the company's performance. The information is sourced from Reuters.
